Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Share:
Related JAZZ
The Wall Street Research Making Waves Today
Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How
Alcobra, Jazz Pharmaceuticals, Nippon Telecom and Toyota Motor highlighted as Zacks Bull and Bear of the Day (Zacks)

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jun 2015UBSMaintainsBuy
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters